Subscription period postponed for the rights issue. Other conditions remain unchanged

SpectraCure AB (publ) postpones the subscription period for the rights issue which was announced on 5 May 2020. The new subscription period is between Friday, 5 June 2020 and Tuesday, 23 June 2020 inclusive. All other terms and conditions of the rights issue remain unchanged.

The Board of Directors of SpectraCure AB (publ) has resolved to postpone the subscription period for the rights issue which was announced on 5 May 2020. The new subscription period is between Friday, 5 June 2020 and Tuesday, 23 June 2020 inclusive. The reason for this decision is that the registration of the prospectus prepared in conjunction with the rights issue with the financial supervisory authority (Finansinspektionen) will not be finalized when the subscription period was set to commence, on 2 June 2020, due to delays in the authority's processing times. All other terms and conditions of the rights issue remain unchanged.

Following the resolution, the timetable will be as follows:

4 June 2020                                      Publication date for the prospectus (preliminary)

5 – 23 June 2020                              Subscription period

5 – 18 June 2020                              Trading in unit rights (UR)

5 June onwards                                 Trading in paid subscription units (BTU) Trading will continue until the rights issue is registered
                                                           
with the Swedish Companies Registration Office, and the conclusion of the trading period will
                                                          be announced later.

Around 26 June 2020                          Announcement of the outcome of the rights issue
 

For more information, please contact:

SpectraCure AB (publ), CEO Masoud Khayyami, telephone: +46(0) 70 815 21 90

 

SpectraCure was founded in 2003 as a spin off from Lund University and LTH Faculty of Engineering. The company focuses on cancer treatments with medical systems based on laser light sources, connected to the tumour by way of optical fibers, in combination with a photoreactive drug.The method is referred to as Interstitial Photodynamic Therapy, PDT. The treatment is suitable for internal solid tumours of various kind, such as prostate and pancreatic tumours, but also for example for cancers of the head and neck. www.spectracure.se

Tags:

About Us

SpectraCure's business concept is to, with its proprietary and patent-pending system, cure internal cancer tumors, prolong survival for cancer patients, and to act as complementary treatment options for other cancer treatments.